HC Wainwright Has Bearish Forecast for QUIT FY2029 Earnings

Achieve Life Sciences, Inc. (NASDAQ:QUIT) – Investment analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for shares of Achieve Life Sciences in a research report issued to clients and investors on Wednesday, November 11th. HC Wainwright analyst B. Folkes now expects that the company will earn $0.92 per share for the year, down from their prior estimate of $0.97. HC Wainwright also issued estimates for Achieve Life Sciences’ FY2030 earnings at $1.39 EPS.

A number of other research analysts have also recently commented on the company. Weiss Ratings initiated coverage on Achieve Life Sciences in a research note on Wednesday. They issued a “sell (d-)” rating for the company. Zacks Research initiated coverage on Achieve Life Sciences in a research note on Tuesday. They issued a “hold” rating on the stock. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

Achieve Life Sciences Trading Down 100.0%

About Achieve Life Sciences

Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead product candidate, cytisinicline, is being studied as a potential aid for people seeking to stop smoking or using other nicotine products. Cytisinicline is a plant-derived compound that acts on nicotine receptors in the brain. The company is conducting clinical development with the goal of obtaining regulatory approval; the candidate is not an approved treatment.